MARKET INDEX
KOSPI4,873.87▼ 5.14%
KOSDAQ650.84▼ 4.96%
S&P 5007,175.83▼ 2.02%
NASDAQ23,879.20▼ 2.25%
USD/KRW1,337.32▲ 3.70 (+0.28%)
WTI Crude$83.00▲ 0.68%
BTC/USD$61,391▼ 0.83%
KOSPI4,873.87▼ 5.14%
KOSDAQ650.84▼ 4.96%
S&P 5007,175.83▼ 2.02%
NASDAQ23,879.20▼ 2.25%
USD/KRW1,337.32▲ 3.70 (+0.28%)
WTI Crude$83.00▲ 0.68%
BTC/USD$61,391▼ 0.83%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

Celltrion Pharm Submits Corrective Measures to FDA Following Cheongju Plant Inspection

Celltrion Pharm has submitted corrective measures and third-party verification to the FDA after its Cheongju plant was classified as 'Official Action Indicated' (OAI).

Celltrion Pharm Submits Corrective Measures to FDA Following Cheongju Plant Inspection
MTIMES Archive / Photo

Third-party independent verification results submitted to FDA; company seeks follow-up meeting to discuss acceptance of responses.

No negative impact on product quality or patient safety identified; no additional measures such as warning letters or import bans issued.

Celltrion Pharm (068760), which was recently notified by the U.S. Food and Drug Administration (FDA) that its Cheongju plant has been classified as 'Official Action Indicated' (OAI), has confirmed the submission of key corrective measures and third-party independent verification results to the agency. The company has also completed a product impact assessment regarding the inspection findings and is currently pursuing a follow-up meeting with the FDA to discuss the acceptance of its submitted responses.

According to reports on the 20th, Celltrion Pharm has finalized its responses and product impact assessments concerning the issues raised during the FDA's inspection of the Cheongju facility in August.

A representative from Celltrion Pharm stated, "We have completed the responses to the inspection findings and the product impact assessment. The results confirmed that there is no negative impact on product quality or patient safety."

The official added, "We have submitted the key corrective measures and the results of the third-party independent verification to the FDA," noting that the company plans to hold a meeting with the agency to discuss the adequacy of these submissions.

Zymfentra supply to the U.S. remains normal; no additional regulatory actions beyond OAI classification

On the 19th, reports emerged that the Celltrion Pharm Cheongju plant had been classified as OAI following an FDA inspection. As the Cheongju plant serves as the production hub for the pre-filled syringe (PFS) version of Celltrion's autoimmune disease treatment, Zymfentra, market attention has focused on the potential impact on U.S. supply.

In a phone interview, Celltrion Pharm confirmed that the production and shipment of existing approved products, including Zymfentra, are proceeding normally and that there are no changes to its U.S. supply chain. The company did not disclose whether the Zymfentra PFS production facility was specifically included in the OAI classification.

The company maintains that it has not received any additional regulatory notices. "To date, we have not received any other measures such as warning letters, import bans, or sales suspensions; we have only received the notification of the OAI classification," the representative stated.

FDA inspection classifications are categorized into No Action Indicated (NAI), Voluntary Action Indicated (VAI), and Official Action Indicated (OAI). An OAI classification indicates that regulatory or administrative action is recommended, but it does not automatically lead to the issuance of a warning letter or an import ban.

The FDA determines its follow-up response after reviewing inspection results, company responses, and corrective action documentation. To resolve an OAI classification, the FDA must verify the appropriateness and implementation of the corrective measures.

"We are working to fully resolve the identified issues through additional inspections," said a Celltrion Pharm official. "We will continue to communicate with the FDA to maintain stable quality and product supply."

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

Urgent Diagnosis: Is the Korean Market a Playground for Foreign Short Sellers?Urgent Diagnosis: Is the Korean Market a Playground for Foreign Short Sellers?The Robotaxi Arms Race: Can Waymo Maintain Its Lead Amid Safety Hurdles?The Robotaxi Arms Race: Can Waymo Maintain Its Lead Amid Safety Hurdles?South Korea Surpasses $1 Trillion in Annual Exports for First Time, Joining Global EliteSouth Korea Surpasses $1 Trillion in Annual Exports for First Time, Joining Global EliteFed Minutes Reveal Consensus for Further Hikes; Wall Street Divided on January OutlookFed Minutes Reveal Consensus for Further Hikes; Wall Street Divided on January Outlook
HomeTOP10AlmatenPicksCorpAlgiten